Abstract
Hematological cancers, such as leukemias and lymphomas, exhibit a high rate of resistance to conventional treatments, demanding new therapeutic approaches. This project proposes the development of hybrid inhibitors that simultaneously target HDAC6 and JAK3, proteins associated with tumor proliferation and therapy resistance. The originality of the proposal lies in the use of bioisosterism…